Physician profile
Duke Oscar Kasprisin
NPI 1891014262
$802,188.81
in general payments reported to CMS, 2019-2025
4 companies · $90K in 2025
The $90K reported for 2025 was more than what 98% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146K · 2020: $145K · 2021: $110K · 2022: $90K · 2023: $109K · 2024: $112K · 2025: $90K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $303K · Travel and Lodging: $6,849 · Royalty Or License: $435 · Food and Beverage: $94.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $303,375.00 |
| Travel and Lodging | $6,849.35 |
| Royalty Or License | $435.00 |
| Food and Beverage | $94.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xtant Medical INC | $473,615.28 | 2021-2025 | |
| Bacterin International INC | $268,524.75 | 2019-2020 | |
| Amnio Technology, LLC | $60,000.00 | 2019-2024 | |
| X-Spine Systems, INC. | $48.78 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Duke Kasprisin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.